Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | Journal of Neuroinflammation

Fig. 6

From: Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes

Fig. 6

Effect of MW150 treatment on microglia closely associated with Aβ plaques and microglia-internalized Aβ in the cortex of APP/PS1 KI mice. a Representative images of Imaris 3D reconstruction of plaques. A region of interest (ROI) was generated by expanding the plaque volume by a 15 μm radius from the edge of the large plaques (larger than 10,000 voxels). This 3D ROI (shown in gray) included the Aβ plaque, and a region near the plaque. IBA1+ cells in this ROI (shown in cyan) were surface rendered to create a 3D volume of all IBA1 positive staining in the ROI. The IBA1 positive staining in the 3D ROI distinguishes plaque-associated microglia (shown in cyan) compared to microglia away from plaques (shown in green). b Volume of surface rendered IBA1+ cells within 15 μm radius around large plaques was significantly increased in KI + MW150 mice compared to KI + veh treatment (p = 0.0397). c Representative image of microglia reconstruction with DAPI stained nuclei showing 6E10 staining within IBA1+ cell cytoplasm. d Microglia-internalized Aβ, as measured by 6E10 staining within surface rendered IBA1+ cells, was not significantly different between the KI + MW150 compared to KI + veh. (n = 11 KI + veh; n = 14 KI + MW150). Data are mean ± SEM. Source data is available in Additional file 3: Table S3

Back to article page